Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
10:46 | FDA approves Sanofi and Regeneron's Dupixent for bullous pemphigoid | ||
Di | Pharmaceutical Technology Excellence Awards 2025: i3 Membrane | ||
Di | Overcoming technical challenges in gene therapy product fill-finish operations | ||
Di | Zambon gains Chinese regulatory authority approval for Fluimucil IV | ||
Di | Navamedic signs agreement to acquire dne pharma | ||
Di | Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug | ||
Di | FDA genAI reviews hinge on clarity of dossiers | ||
Di | FDA approves AstraZeneca and Daiichi Sankyo's Datroway for NSCLC | ||
Mo | Bayer's Eylea market grip set to slip as Alvotech biosimilar closes in | ||
Mo | Harbour BioMed partners Otsuka on new T-cell therapy | ||
Mo | Bridging the gap: A comprehensive approach to social determinants of health | ||
Mo | EC approves argenx's efgartigimod alfa for CIDP treatment | ||
Mo | From discovery to delivery: making therapies reach patients faster | ||
Fr | Madrigal poised to enter European MASH market after CHMP endorsement | ||
Fr | London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape | ||
Fr | Podcast: Uses of blockchain in healthcare | ||
Fr | Novartis' ribociclib approved in Canada for early breast cancer | ||
Fr | FDA cell and gene therapy director exit increases 'volatility' for sector | ||
Fr | NSW government invests $13.39m in life-changing therapies | ||
Fr | DoH - Abu Dhabi and Sanofi link for vaccine development | ||
Do | CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024 | ||
Do | UK and US governments pursue contrasting vaccine strategies | ||
Do | Actio gains $66m to advance small molecule therapeutics pipeline | ||
Do | BioOrbit eyes 2026 for pre-clinical trials of space manufactured protein crystals | ||
Do | Eli Lilly and Eisai's Alzheimer's drugs denied NHS use due to high costs |